PIK3CB and neoplasm: The hyperactive PI3K signaling, whether it is the consequence of PI3KCA mutations or PTEN deletions, can promote the establishment of tumor suppression by developing tumors,467 suggesting the potential use of PI3K inhibitor to enhance the efficacy of immunotherapy in the clinic (Fig. 6a).